tradingkey.logo
tradingkey.logo
Suchen

GeneDx Holdings Corp

WGS
Zur Watchlist hinzufügen
71.710USD
+3.060+4.46%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
2.13BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über GeneDx Holdings Corp Unternehmen

GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

GeneDx Holdings Corp Informationen

BörsenkürzelWGS
Name des UnternehmensGeneDx Holdings Corp
IPO-datumSep 04, 2020
CEOStueland (Katherine A)
Anzahl der mitarbeiter1000
WertpapierartOrdinary Share
GeschäftsjahresendeSep 04
Addresse333 Ludlow Street
StadtSTAMFORD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl06902
Telefon18887291206
Websitehttps://sema4.com/
BörsenkürzelWGS
IPO-datumSep 04, 2020
CEOStueland (Katherine A)

Führungskräfte von GeneDx Holdings Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
185.99K
-20.43%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
39.95K
+12.54%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
26.33K
-25.95%
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
20.13K
--
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Ms. Katherine A. Stueland
Ms. Katherine A. Stueland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
185.99K
-20.43%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
39.95K
+12.54%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
26.33K
-25.95%
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
20.13K
--
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von GeneDx Holdings Corp?

Die fünf größten Anteilseigner von GeneDx Holdings Corp sind: Mr. Joshua Ruch

Was ist die größte Einnahmequelle von GeneDx Holdings Corp?

Am 2026Q4 erzielte das Geschäft mit Patients with third party insurance für GeneDx Holdings Corp den höchsten Umsatz in Höhe von 345.24M, was 80.75% des Gesamtumsatzes entspricht.